Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative 5FU-Cisplatin-Cetuximab in Gastric and GEJ Adenocarcinoma
NCT01360086Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jun 2011
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoints: Objective Response Rate at 3 months and Non-toxicity rate at 3 months. Started Jun 2011; status: completed.
02
Drugs
KL-140
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01360086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360086.